98%
921
2 minutes
20
Purpose: Although proton relative biological effectiveness (RBE) depends on factors like linear energy transfer (LET), tissue properties, dose, and biological endpoint, a constant RBE of 1.1 is recommended in clinical practice. This study surveys proton institutions to explore activities using functionalities beyond a constant proton RBE.
Methods: Research versions of RayStation integrate functionalities considering variable proton RBE, LET, proton track-ends, and dirty dose. A survey of 19 institutions in Europe and the United States, with these functionalities available, investigated clinical adoption and research prospects using a 25-question online questionnaire.
Results: Of the 16 institutions that responded (84% response rate), 13 were clinically active. These clinical institutions prescribe RBE = 1.1 but also employ planning strategies centered around special beam arrangements to address potentially enhanced RBE effects in serially structured organs at risk (OARs). Clinical plan evaluation encompassed beam angles/spot position (69%), dose-averaged LET (LET) (46%), and variable RBE distributions (38%). High ratings (discrete scale: 1-5) were reported for the research functionalities using linear LET-RBE models, LET, track-end frequency and dirty dose (averages: 4.0-4.8), while LQ-based phenomenological RBE models dependent on LET scored lower for optimization (average: 2.2) but congruent for evaluation (average: 4.1). The institutions preferred LET reported as LET (94%), computed in unit-density water (56%), for all protons (63%), and lean toward LET-based phenomenological RBE models for clinical use (> 50%).
Conclusions: Proton institutions recognize RBE variability but adhere to a constant RBE while actively mitigating potential enhancements, particularly in serially structured OARs. Research efforts focus on planning techniques that utilize functionalities beyond a constant RBE, emphasizing standardized LET and RBE calculations to facilitate their adoption in clinical practice and improve clinical data collection. LET calculated in unit-density water for all protons as input to adaptable phenomenological RBE models was the most suggested approach, aligning with predominant clinical LET and variable RBE reporting.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11712586 | PMC |
http://dx.doi.org/10.1002/acm2.14535 | DOI Listing |
Med Phys
September 2025
Department of Accelerator and Medical Physics, National Institutes for Quantum Science and Technology (QST), Chiba, Japan.
Background: Multi-ion radiotherapy using carbon, oxygen, and neon ions aims to improve local control by increasing dose-averaged linear energy transfer (LET) in the target. However, there has been limited understanding of how to utilize variables for multi-ion treatment planning such as the selection and arrangement of ion species.
Purpose: An in silico study was conducted to explore the feasibility of increasing a minimum LET, and the optimal selection and arrangement of ion species in multi-ion therapy for increasing LET in tumors of varying sizes mimicking bone and soft tissue sarcomas (BSTS).
Oral Dis
September 2025
Clinical Department, Radiation Oncology Unit, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy.
Aim: To evaluate the outcomes of combining carbon ion radiotherapy boost (CIRTb) with photons (Ph) or protons (PT) for locally advanced salivary gland and sinonasal cancers (SGCs and SNCs).
Materials And Methods: Sixty-nine patients with SGCs and SNCs received CIRTb to high-risk CTV and Ph or PT to low-risk CTV (LR-CTV) from October 2014 to September 2022. Two-year local relapse-free survival (LRFS) was analyzed with Kaplan-Meier.
J Neurooncol
September 2025
Department of Radiation Oncology, Massachusetts General Hospital, Boston, USA.
Purpose: Cranial irradiation is associated with health-related quality of life (HRQoL) deficits in childhood cancer survivors. We investigated the relationship between radiation dose to brain substructures and HRQoL in children with brain tumors treated with proton beam therapy (PBT).
Methods: Data were obtained from children in the Pediatric Proton/Photon Consortium Registry who received PBT for primary brain tumors between 2015 and 2021.
Exp Dermatol
September 2025
Department of Surgery, Chang Bing Show Chwan Memorial Hospital, Lukang, Taiwan.
Radiation dermatitis is a common side effect of radiotherapy, affecting up to 95% of cancer patients receiving radiation therapy and often leading to skin damage, inflammation, and ulceration. The pathogenesis of radiation dermatitis involves complex mechanisms, such as the production of reactive oxygen species (ROS) and sustained inflammatory responses. Current treatments, including topical steroids, moisturisers, and non-steroidal anti-inflammatory drugs (NSAIDs), often provide limited efficacy, primarily addressing symptoms rather than the underlying pathophysiological processes.
View Article and Find Full Text PDFHead Neck
September 2025
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Background: Flap complications following maxillectomy, reconstruction, and adjuvant proton beam therapy (PBT) for primary maxillary and sinonasal malignancies are not well described.
Methods: This retrospective cohort study included consecutive patients treated between 2016 and 2023 from a single-institutional database.
Results: Thirteen patients were identified with a median follow-up of 26 months.